NCT04574830View on ClinicalTrials.gov

Study to Evaluate Biomarkers and Clinical Manifestations in Individuals With Glycogen Storage Disease Type III (GSD III)

CompletedOBSERVATIONAL
Enrollment

18

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Glycogen Storage Disease Type III
Interventions
OTHER

No Intervention

No Intervention

Trial Locations (4)

77030

University of Texas Medical School, Houston

80045

Colorado Children's Hospital, Aurora

92697

University of California, Irvine

92868

Children's Hospital Orange County, Orange

All Listed Sponsors
lead

Ultragenyx Pharmaceutical Inc

INDUSTRY

NCT04574830 - Study to Evaluate Biomarkers and Clinical Manifestations in Individuals With Glycogen Storage Disease Type III (GSD III) | Biotech Hunter | Biotech Hunter